Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation

Andrew E Teschendorff1*, Allison Jones2, Heidi Fiegl3, Alexandra Sargent4, Joanna J Zhuang1,2, Henry C Kitchener4 and Martin Widschwendter2*

Abstract

Background: Recently, it has been proposed that epigenetic variation may contribute to the risk of complex genetic diseases like cancer. We aimed to demonstrate that epigenetic changes in normal cells, collected years in advance of the first signs of morphological transformation, can predict the risk of such transformation.

Methods: We analyzed DNA methylation (DNAm) profiles of over 27,000 CpGs in cytologically normal cells of the uterine cervix from 152 women in a prospective nested case-control study. We used statistics based on differential variability to identify CpGs associated with the risk of transformation and a novel statistical algorithm called EVORA (Epigenetic Variable Outliers for Risk prediction Analysis) to make predictions.

Results: We observed many CpGs that were differentially variable between women who developed a non-invasive cervical neoplasia within 3 years of sample collection and those that remained disease-free. These CpGs exhibited heterogeneous outlier methylation profiles and overlapped strongly with CpGs undergoing age-associated DNA methylation changes in normal tissue. Using EVORA, we demonstrate that the risk of cervical neoplasia can be predicted in blind test sets (AUC = 0.66 (0.58 to 0.75)), and that assessment of DNAm variability allows more reliable identification of risk-associated CpGs than statistics based on differences in mean methylation levels. In independent data, EVORA showed high sensitivity and specificity to detect pre-invasive neoplasia and cervical cancer (AUC = 0.93 (0.86 to 1) and AUC = 1, respectively).

Conclusions: We demonstrate that the risk of neoplastic transformation can be predicted from DNA methylation profiles in the morphologically normal cell of origin of an epithelial cancer. Having profiled only 0.1% of CpGs in the human genome, studies of wider coverage are likely to yield improved predictive and diagnostic models with the accuracy needed for clinical application.

Trial registration: The ARTISTIC trial is registered with the International Standard Randomised Controlled Trial Number ISRCTN25417821.

Background
It has been proposed that epigenetic variation may contribute to the risk of complex genetic diseases like cancer and that differential exposure to environmental risk factors may underlie much of this variation [1,2].

Consistent with this view, a recent study has shown that regions that are differentially methylated between normal and cancer tissue appear to be highly variable in cancer itself, and that identification of cancer-relevant markers may therefore benefit from statistics that measure differential variability [3]. Based on these insights, we here aimed to demonstrate that analysis of epigenetic variability in prospectively collected normal cells can predict the risk of future morphological transformation.

In order to demonstrate this in humans, two requirements are mandatory: the cells that are used for...
epigenetic analyses need to be (i) the cells of origin for the studied cancer, and (ii) they need to be collected years in advance of the onset of cytological and morphological signs of cancer. Currently, the only human organ that meets these two requirements is the uterine cervix. Thus, we used Illumina Infinium technology [4] to measure DNA methylation (DNAm) at 27,578 CpG sites in cytologically entire normal cells (liquid-based cytology (LBC) samples) from the uterine cervix of 152 women (aged 19 to 55 years) in a nested prospective case-control study within ARTISTIC (A Randomised Trial of HPV Testing in Primary Cervical Screening [5,6]). Prospective cases were women who developed a cervical intraepithelial neoplasia of grade 2 or higher (CIN2+) within 3 years of sample draw, while controls were women who remained disease-free. To further support our data we used completely independent LBC samples with abnormal cytology and associated controls, as well as cervical cancer tissue and normal cervix specimens.

Methods
Study population
The ARTISTIC trial
The LBC samples we analyzed were collected from women as part of the ARTISTIC trial [5,6]. All women underwent two screening rounds with an interval of 3 years. Within the ARTISTIC trial, women, aged 19 to 64 years who were undergoing routine screening as part of the English National Health Service Cervical Screening Programme in Greater Manchester were randomly assigned in a ratio of 3:1 to either combined LBC and human papilloma virus (HPV) testing where the results were revealed and acted on, or to combined LBC and HPV testing where the HPV result was concealed from the patient and investigator. There were a total of 24,510 eligible women at entry. In the first round of screening 453 women had CIN2+. In the second round of screening 75 women (who were screen-negative in the first round and who had a sample stored from the first round) had developed CIN2+ (44 were HPV-positive and 31 were HPV-negative in the first round). Seventy-seven women who had not developed any cytological changes were matched (age and HPV status in round 1) to the cases. The cytologically normal samples from round 1 from these 152 women were used for DNAm analysis. Further details, cytology and HPV scoring are described in Additional file 1. This trial is registered with the International Standard Randomised Controlled Trial Number ISRCTN25417821.

DNA methylation nested case control study
A total of 152 samples in a prospective nested case control study within ARTISTIC were selected for DNAm analysis. Cases were 75 women who had normal cytology in screening round 1 but demonstrated CIN2+ after 3 years in round 2. Controls were 77 women who had normal cytology at entry and in the second screening round. Cases and controls were matched for age (Wilcoxon rank sum test P = 0.95) and HPV status: 92 were HPV-positive (44 cases and 48 controls) and 60 were HPV-negative (31 cases and 29 controls) at entry (Fisher test P = 0.74). Informed consent was obtained from the main study population and this study has been approved by the ethical committee (National Research Ethics Service Reference Number 10/H1107/15).

Other DNA methylation data sets
In addition to the nested case control prospective study within ARTISTIC, we used two additional DNAm data sets that were also generated using the same Illumina Infinium 27 k platform. Set 1 comprised a total of 30 LBC samples (19 HPV-negatives and 11 HPV-positives) with normal cytology and 18 LBC samples (all HPV-positive) with CIN2+, as described in [7]. Set 2 comprised a total of 63 cervical tissue samples: 48 cervical cancers, 15 normals. The normal cervical tissue samples were from women (mean age 55.4 years) who underwent a hysterectomy for fibroids of the uterine corpus, that is, these women did not have fibroids in the uterine cervix. The 48 cervical cancer specimens were from women (matched for age with mean age 56.8 years) who were treated at the Innsbruck Medical University. Of these 48 cancers, 26 were of stage 1, 10 of stage 2, 4 of stage 3 and 7 of stage 4 (1 sample had missing stage information). In terms of grade, 7 were of grade 1, 28 of grade 2 and 11 of grade 3 (2 samples had no grading). All specimens were obtained with informed consent and approval from the ethics committee UN4044-290/4.9.

DNA extraction and methylation assay
The DNA extraction protocol is described in Additional file 1. Genome-wide methylation analysis using the Illumina Infinium Methylation27K beadchip (Illumina Inc., USA, WG-311-1201) was performed. This chip interrogates the methylation status of over 27,000 CpG sites throughout the human genome, covering the promoters of over 14,000 genes [4]. Further details are in Additional file 1.

Data availability
All data in this manuscript have been deposited in the Gene Expression Omnibus repository [8] under accession number [GSE30760].

mRNA expression data of normal cervical and cervical cancer tissue
We used the publicly available normalized expression data (all Affymetrix) from the Gene Expression Omnibus with accession numbers [GSE9750] [9], [GSE7803] [10], and [GSE6791] [11]. For each downloaded data set we only selected the normal squamous cervix epithelial and squamous cervical cell carcinoma samples: for
To identify CpGs associated with age (aCpGs) we used supervised analyses [7]. The raw DNAm data were subject to a similar quality analysis are given below.

**Statistical methods**

Full details of statistical methods are in Additional file 1. Brief descriptions of the different parts of the statistical analysis are given below.

**Quality control and inter-array normalization**

The raw DNAm data were subject to a similar quality control procedure as used in our previous publication [7].

**Supervised analyses**

To identify CpGs associated with age (aCpGs) we used surrogate variable analysis [15]. False discovery rate (FDR) estimation was implemented as in the q-value package [16]. To identify age-independent variable CpGs (vCpGs), we adjusted the data for age, and subsequently estimated the variances for each CpG. Because of the heteroscedasticity of $\beta$-values [17], we also estimated the variance using $R$-values (defined as $R = M/IL$) [18]. To identify differentially variable CpGs (DVCs) between prospective CIN2+ cases and normals, we used Bartlett’s test [19]. In doing so, variances were estimated after the methylation profiles were linearly adjusted for age within each phenotype.

**EVORA: Epigenetic Variable Outliers for Risk Prediction Analysis**

Full details and the model assumptions on which EVORA is based are described in Additional file 1. There are three important statistical aspects to EVORA: (i) identification of candidate risk CpGs; (ii) identification of samples that constitute methylation outliers; and (iii) a method for assigning risk to each sample, which is robust and independent of the scale used. For (i) we use Bartlett’s test [19], since our hypothesis is that DVCs defined by outlier profiles are more likely to define risk CpGs [3]. To define outliers in a scale-independent fashion (ii) we use the COPA (Cancer Outlier Profile Analysis) transformation [20]. Lastly, to assign a risk score to a sample, we use an adaptive index algorithm framework [21]. EVORA is freely available as an R-package (evora) [22].

**Results**

DNA methylation variability is increased in cytologically normal cells predisposed to neoplasia

A stringent quality control and inter-array normalization procedure resulted in a normalized data matrix of methylation values ($\beta$-values, $0 < \beta < 1$) over 24,039 CpGs and 152 samples (Methods). Prospective cases ($n = 75$) and controls ($n = 77$) were matched for age and HPV status (Methods). Following the suggestion that epigenetic variability may mark genes that contribute to the risk of cancer [1,3,23], we hypothesized that differential variability in normal tissue might be associated with an increased risk of neoplasia. We thus derived a list of CpGs that showed significantly different (age-adjusted) variability between future (CIN2+) cases and controls (DVCs) (Methods). We observed many DVCs (Figure 1a) and among the top 500 (FDR < 0.0001; Additional file 2) the majority (73%) were more variable in future cases (Figure 1c). The set of DVCs was largely unchanged if variability was not adjusted for age or if also adjusted for HPV status (Additional file 3). In contrast, testing for differential methylation using $t$-statistics (differentially methylated CpGs (DMCs)) did not yield genome-wide significance levels (FDR ~0.6 for the top 50 CpGs; Figure 1b). DVCs that showed significantly higher variance in future cases (hypervariable DVCs) generally exhibited small yet consistent increases in mean methylation levels (Figure 1d; Additional file 2). Inspection of typical methylation profiles of such DVCs revealed that the increased or decreased variability was due to approximately 20 to 30% changes in DNAm present in only a relatively small number of ‘outlier’ samples (Figure 1d; Additional file 4). Developmental genes, and in
particular polycomb group targets (PCGTs) [24] (see Additional file 1 for precise definition), were enriched only among the DVCs showing increased variance in the normal cells of prospective cancer cases (odds ratio = 4.9 (3.9 to 6.3), \( P < 1 \times 10^{-31} \)) and were six times more likely to exhibit higher variability in prospective cases than lower (Additional file 5). PCGTs were also the most highly enriched gene category out of a total of 6,173 gene sets in a Gene Set Enrichment Analysis [25] (Additional file 6). Random permutation of sample labels also showed that this enrichment could not have arisen by chance (Additional file 5). Thus, all these results indicate that increased DNAm variability affects PCGTs and is an intrinsic property of normal cells predisposed to neoplasia.

**Age-associated variation in DNA methylation also correlates with the risk of neoplasia**

An unsupervised singular value decomposition and a supervised linear regression analysis (adjusted for CIN2 + status) both confirmed a strong age-associated signature (644 CpGs at FDR < 0.05) with the majority (392,
61%) hypermethylated with age (Additional files 7 and 8). Interestingly, we observed that the 644 CpGs undergoing age-associated changes in DNAm (aCpGs) showed specific directional changes associated with the future development of CIN2+ even though these changes were not individually significant (Additional file 9). Specifically, those CpGs undergoing significant hypermethylation with age were generally also hypermethylated in future CIN2+ cases (Additional file 9). To test further if age-hypermethylated aCpGs are indeed associated with CIN2+, we compared their methylation levels in an independent data set (also generated with the Illumina 27 k platform) consisting of 30 normal and 18 age-matched CIN2+ samples (Set 1, Methods) [7]. The mean methylation level of these aCpGs was also significantly higher in the CIN2+ samples of this set (Additional file 10).

**Significant overlap of hypervariable DVCs and age-hypermethylated aCpGs**

Next, we explored the relationship between DVCs and aCpGs. Many CpGs showing age-associated hypermethylation also showed significant increases in (age-adjusted) variability within the normal tissues of future CIN2+ cases (Additional file 9). To test further if age-hypermethylated aCpGs are indeed associated with CIN2+, we compared their methylation levels in an independent data set consisting of 30 normal and 18 age-matched CIN2+ samples (Set 1, Methods) [7]. The mean methylation level of these aCpGs was also significantly higher in the CIN2+ samples of this set (Additional file 10).

**Differentially hypervariable CpGs predict risk of intraepithelial cervical neoplasia**

Based on these results, we proposed the following model in which epigenetic variance may be used to predict the risk of neoplastic transformation. Since the typical DVC methylation profile (Figure 1d) is one in which a small number of samples exhibit increased outlier methylation (≥ 20% methylation change), we hypothesized that cancer-risk in a given sample may be associated with the number of such risk CpGs (hypervariable DVCs/hypermethylated aCpGs) becoming ‘methylation hits’ (Figure 3a). To test this idea, we applied a novel statistical algorithm called EVORA (Methods; Figure 3a), which aims to assess the risk of neoplastic transformation from the number of methylation outliers. Using multiple training/test set partitions, we found that EVORA could predict the future risk of CIN2+ in blind test sets (area under the curve (AUC) = 0.66 (0.58 to 0.75), P < 0.05; Figure 3b), while an analogous classifier based on differences in mean methylation levels could not (AUC = 0.51 (0.30 to 0.72), P = 0.46; Figure 3c).

**Risk CpGs identified in normal cells can detect intraepithelial cervical neoplasia and cervical cancer**

EVORA identified a total of 140 risk CpGs (hypervariable DVCs and hypermethylated aCpGs; Figure 4a; Additional file 11), of which 69 mapped to PCGTs. We postulated that this pool of 140 risk CpGs would also necessarily diagnose CIN2+ status, since for established neoplastic cells we would expect an even higher fraction of these CpGs to be hypermethylated. Indeed, in an independent Illumina Infinium 27 K methylation data set of normal cervical smears and age-matched CIN2+ samples (set 1; Methods), EVORA was able to predict CIN2+ status with very high accuracy (Figures 3d and 4b). Importantly, while the risk scores of the normal samples in ARTISTIC and set 1 were comparable to each other, the scores of the CIN2+ samples were significantly higher than those of normal cells that only become CIN2+ within 3 years (Figure 5), reflecting a progressive increase from normal cells at low risk, to normal cells at high risk, and finally to cells in a pre-invasive neoplastic state. Importantly, risk CpGs (that is, differentially variable CpGs) identified from the ARTISTIC cohort predicted CIN2+ status better than CpGs that were not differentially variable, even if they mapped to PCGTs (Figure 6). Since risk CpGs performed similarly irrespective of PCGT status (Figure 6), this indicates that differential variability is the key feature of cells at risk of morphological transformation and not PCGT status.

Next, we explored the methylation profiles of the 140 risk CpGs in an independent set of cervical cancers and
The outlier risk scores were significantly reduced in cohort 2 owing to the fact that risk CpGs exhibited much more of a bi-modal methylation pattern between cancer and normal tissue; that is, risk CpGs were invariably either hemi- or fully methylated across a high proportion of the cancers (Figure 4d). Nevertheless, a small subset of risk CpGs retained their outlier profiles in

**Figure 2 Relation between differentially variable and age-associated CpGs.** (a) Bartlett test P-values (on -log10 scale) of CpGs indicating significance of differential variability (between prospective CIN2+ and controls) (y-axis) versus their average β-value across all samples (x-axis). CpGs undergoing age-associated (aCpG) hypermethylation (hyperM) or hypomethylation (hypoM) are colored as indicated. (b) The ratio (on log scale) of variability in prospective CIN2+ to variability in controls (y-axis) versus significance level (x-axis). Skyblue (orange) denotes CpGs significantly hypermethylated (hypomethylated) with age (aCpGs) in normal cells from uterine cervix. The green dashed line represents the FDR cutoff value of 0.05 for calling DVCs. (c) Venn diagram illustrating overlaps of age-hypermethylated CpGs with DVCs that are hypervariable (hyperV) in prospective CIN2+, and with PCGT CpGs. A total of 41 CpGs overlapped between all three categories and 20,917 CpGs were in none of the three categories. The P-value (estimated from a multiple binomial test) indicates the random chance of observing 41 or more overlapping CpGs. Among these CpGs, we give the number that are significantly differentially variable (FDR < 0.05, green dashed line) and their distribution in terms of increased or decreased variance in future CIN2+ cases. P-value is from a binomial test.

The outlier risk scores were significantly reduced in cohort 2 owing to the fact that risk CpGs exhibited much more of a bi-modal methylation pattern between cancer and normal tissue; that is, risk CpGs were invariably either hemi- or fully methylated across a high proportion of the cancers (Figure 4d). Nevertheless, a small subset of risk CpGs retained their outlier profiles in...
Figure 3 Epigenetic variable outliers for risk prediction analysis (a) Flowchart describing the EVORA model. (i) Age-associated DNA methylation (DNAm) variation and age-independent differentially variable DNAm are both correlated with the risk of prospective neoplasia (CIN2+). aCpGs undergoing age-associated hypermethylation (hyperM) overlap strongly with differential variable CpGs (DVCs) that exhibit increased variance in future CIN2+ cases. This overlap defines, for a given training set, the pool of candidate risk CpGs. (ii) Multiple training/test set partitions in a ten-fold internal cross-validation on COPA-transformed (Methods) methylation profiles is used to optimize the COPA threshold and the set of risk CpGs. (iii) Risk prediction using EVORA: for an independent sample its risk score is estimated as the fraction of risk CpGs with a β-value larger than the optimal threshold, as evaluated in the COPA-basis. (b) EVORA receiver operating characteristic (ROC) curve, AUC and its 95% confidence interval in the ARTISTIC cohort (152 normal samples: 75 future CIN2+, 77 normals). (c) Comparison of C-index (AUC) values obtained using EVORA with a classification algorithm based on detecting differences in mean methylation levels (mean) in the ARTISTIC cohort. Boxplots are over 100 distinct training-test set partitions and P-values are from a Wilcoxon test detecting deviation from the expected null (C-index = 0.5) as well as between the two classification algorithms. (d) EVORA ROC curve in set 1 (48 liquid-based cytology samples: 18 CIN2+, 30 normals). (e) EVORA ROC curve in set 2 (63 cervical tissue samples: 48 cancers, 15 normals). In all ROC curves, AUC values and 95% confidence intervals shown. FPR: false positive rate; Se: sensitivity.
carcinoma) specimens (Methods). The integration was cervical epithelial and 74 cervical cancer (squamous cell profiles over 13,213 genes and encompassing 42 normal we built an integrated data set of mRNA expression risk CpGs show expression changes in cervical cancer, tissue (Figures 3e and 4d). yield a perfect discrimination of normal and cancer EVORA to the original beta methylation scale to better predict risk genes are underexpressed in cervical cancer cervical cancer and EVORA was therefore still highly predictive of cancer status (Figure 4c). Adapting EVORA to the original beta methylation scale to better capture the observed bi-modal methylation profiles yielded a perfect discrimination of normal and cancer tissue (Figures 3e and 4d).

**Risk genes are underexpressed in cervical cancer**

To evaluate if the genes associated with the identified risk CpGs show expression changes in cervical cancer, we built an integrated data set of mRNA expression profiles over 13,213 genes and encompassing 42 normal cervical epithelial and 74 cervical cancer (squamous cell carcinoma) specimens (Methods). The integration was done using a renormalization procedure that we have validated previously [12-14]. Of the 140 risk genes, 86 could be mapped to this merged data set. Comparison of average mRNA levels of our 86 risk genes between normal and cancer tissue confirmed that risk genes showed lower average expression levels in cervical cancer (Additional file 12). Analysis of individual gene statistics further showed that 46 were differentially expressed and that there was a significant skew towards underexpression in cancer (Additional file 12). Moreover, in only 13 of 1,000 random selections of 86 gene sets (Monte Carlo analysis described in Methods) did we observe a skew as significant as the one observed for the risk genes (Additional file 12).

![Figure 4 Heatmaps over risk CpGs](image-url)

Figure 4 Heatmaps over risk CpGs (a-c) Heatmaps of COPA-transformed methylation values for the top 140 risk CpGs that are (i) significantly hypermethylated with age and (ii) show significant increased variability in future CIN2+ cases, as determined in the ARTISTIC cohort. Color codes for COPA scores: yellow = COPA score < 1 (no methylation); skyblue = COPA score < 5. Outliers denoted by blue = methylation COPA score > 5 and black = methylation COPA score > 10. CpGs have been hierarchically clustered using a Manhattan distance metric. Those mapping to PCGs are labeled with their associated gene. Samples have been ordered according to their EVORA risk score as shown in the panels above heatmaps. (a) ARTISTIC cohort: 152 samples (75 prospective CIN2+ (red), 77 no CIN2+ at last follow-up (green)). (b) Set 1: 48 samples (18 CIN2+ (red), 30 normals (green)). (c) Set 2: 63 cervical tissue samples (48 cancers (red), 15 normals (green)). (d) Heatmap depicts the same data matrix as in (c) but with the methylation values on the β-value scale where CpG β-values have been median normalized to zero. The corresponding scores now depict the percentage of methylation hits as measured on the beta-scale.
Discussion

In this work we have addressed two fundamental questions. First, do DNAm changes precede the morphological signs of neoplastic transformation? And second, can these epigenetic changes (a) predict the risk of neoplastic development, and (b) allow detection of early (non-invasive) cancers? We have addressed these questions in the context of the uterine cervix, currently the only human organ allowing relatively easy access to the cell of origin of the associated cancer well in advance of the first morphological signs of neoplastic transformation.

Figure 5 Cross-comparison of EVORA risk scores. Boxplots of EVORA risk scores (y-axis) of the 77 normal LBC samples in ARTISTIC (N(ART)), the 30 normal LBC samples of set 1 (N(Set1)), the 75 prospective CIN2+ LBC samples in ARTISTIC (preCIN2+(ART)), and the 18 CIN2+ samples of set 1 (CIN2+ (Set1)). Wilcoxon test P-values between N(ART) and N(Set1), and between preCIN2+(ART) and CIN2+(Set1) are given.

Figure 6 EVORA AUC values as a function of differential variability and PCGT status. (a, b) Comparison of EVORA AUC measures for four different CpG classes in (a) set 1 consisting of 18 CIN2+ LBC samples and 30 normal LBC samples, and in (b) set 2 consisting of 48 cervical cancers and 15 cervical normal tissues. Of the 140 risk CpGs, 69 mapped to PCGTs (risk-PCGT class) and 71 did not (risk-nonPCGT class). In addition, we randomly selected 70 non-differentially variable, non-age-associated CpGs (nonrisk) that mapped and that did not map to PCGTs. The random selection was done 100 times and AUC values averaged. Also provided are 95% confidence intervals.
Based on the hypothesis that epigenetic variability may reflect exposure to various genetic and non-genetic risk factors (including age), and that differential epigenetic variability may reflect underlying differential exposure to these factors [1,3], we posited that differentially variable methylated CpGs (DVCs) might be potential risk indicators of neoplastic transformation. Our prediction algorithm based on epigenetic variance (EVORA; Figure 3A) could predict, with low but statistically significant accuracy (AUC = 0.66, P < 0.05), prospective CIN2+ status in blind test sets (Figure 3B). In contrast, an analogous classifier that uses differential methylation instead of differential variability statistics could not predict prospective CIN2+ status (Figure 3C). Using EVORA, the set of risk CpGs could also accurately identify independent CIN2+ and cervical cancer samples (AUC > 0.9; Figures 3D, E and 4). Using these additional data sets, we also showed that differential variability is a more important characteristic of risk CpGs (supporting the findings in [3]) than PCGT status (Figure 6). Thus, these results support the view that differential variability is a key characteristic of cells predisposed to morphological transformation.

We have obtained these results in the context of cervical cancer using a study design that was matched for age and HPV status. Since HPV infection is a well-known necessary causal factor for cervical cancer [26], it is thus reasonable to assume that those HPV-negative samples that later developed a CIN2+ will have done so only by acquiring an HPV infection after sample collection [27]. It is important, therefore, to point out that the increased DNA methylation variability at the identified loci only increases the risk of CIN2+ in the background of an existing HPV infection. Given that HPV infection is a necessary but not sufficient factor to cause cervical carcinogenesis (most HPV-infected women do not develop cervical cancer), it is indeed very likely that unknown ‘tumor-suppressor’ factors play a role in determining which HPV-infected women develop a CIN2+. Thus, our data support a model in which increased DNA methylation variability at the identified loci may compromise specific tumor suppressor functions, predisposing HPV-infected women to develop a CIN2+. In this context, it is also important to note that we did not observe HPV infection to have a major effect on DNA methylation and that EVORA risk score itself was not correlated with HPV status (Additional file 13). Nevertheless, we did observe a very weak marginal association of DNA methylation with HPV status within only the prospective CIN2+ sample subgroup (Additional file 13). Thus, while increased DNA methylation variability may synergize with a background HPV infection to increase the risk of CIN2+, HPV infection itself only appears to have a minor effect on DNA methylation patterns in the earliest stages of cervical carcinogenesis. It is possible, however, that HPV infection may cause significant DNA methylation and mRNA changes during the latter stages of carcinogenesis, as reported, for instance, in the case of head and neck cancers [11,28,29].

In line with our hypothesis that epigenetic variable CpGs are involved in carcinogenesis, we find that they become more homogeneously methylated (that is, either hemi- or fully methylated) across cancers (Figure 4D), in stark contrast to their heterogeneous (that is, unmethylated versus hemi- or fully methylated) outlier profiles in potent CIN2+ and established CIN2+ cells (Figure 4A, B). This transition from heterogeneous outlier profiles in the earliest stages of cervical carcinogenesis to more homogeneous methylation profiles in the more advanced cancer stage points towards a dynamic process in which DNA methylation is initially acquired in a largely stochastic manner, as hypothesized in [1], but that later becomes more homogeneous and deterministic. However, we should point out that risk CpGs remain highly variably methylated across the invasive cancers, as previously reported in [3].

Interestingly, the heatmaps of the prospective and pre-invasive cancer series (Figures 4A, B) also revealed the existence of a striking bi-modality within the cases only, with a small subset of cases exhibiting a highly correlated pattern of CpG methylation, in contrast to the more stochastic pattern of methylation seen in the majority of samples. It is particularly interesting that the risk CpGs identified in ARTISTIC generated this same characteristic stochastic versus correlated bi-modal pattern in the CIN2+ samples of set 1. To investigate this further, we used an unsupervised clustering algorithm to divide up the CIN2+ samples (of set 1) and the cervical cancers (of set 2) each into two clusters according to the average level of methylation over all CpGs mapping to CpG islands excluding the 140 risk CpGs (Additional file 14). Interestingly, in both sets, the EVORA risk scores obtained from the 140 risk CpGs were significantly higher for the cases exhibiting the higher global levels of CpG island methylation (Additional file 14). Thus, the risk CpGs appear to correlate particularly strongly with CIN2+ samples and cervical cancers of overall higher CpG island methylation levels. It will be interesting, therefore, to explore the relationship, if any, of the identified risk CpGs to a potential CpG island methylator phenotype (CIMP) [30,31] in cervical cancer. Using an unsupervised consensus clustering over the 1,000 most variable CpGs in the ARTISTIC set - that is, the unsupervised procedure used in [31,32] to define a CIMP, did not yield a clear CIMP, nor did the clusters correlate with the EVORA risk scores, suggesting that there is no CIMP (in the sense defined in [31,32]) present three years in advance of morphological transformation (Additional file 15).
Over the years extensive evidence has accumulated to demonstrate that PCGT methylation is crucially involved in carcinogenesis [33-37]. Although we have here provided substantial evidence that differential variability is a more fundamental characteristic of transformation than PCGT status (Figure 6), our analyses nevertheless implicate a subset of PCGTs in the earliest stages of carcinogenesis (69 out of the 140 risk CpGs mapped to PCGTs). Numerous risk CpGs were also annotated to genes that have been previously demonstrated to be linked to cervical cancer, including CALCA [38], CXCR4 [39], DCC [40], HOXC10 [10], MYOD1 [41], SFRP4 [42], SOX1 [43], TWIST1 [44] and WT1 [45]. However, we note that only HOXC10 had its risk CpG site located within 200 bp upstream of the transcription start site. In fact, of the 140 risk CpG sites, only 64 were within 200 bp of the start site, and of these only 24 were upstream. Thus, even though we observed the genes associated with our risk CpGs to be frequently underexpressed in cervical cancer, it remains to be seen if methylation of the identified risk CpG sites plays a part in the underlying regulatory mechanism.

Our data also revealed a remarkably strong overlap between CpGs undergoing age-associated hypermethylation in normal tissue and CpGs that were hypervariable in prospective CIN2+ cases. PCGTs made a large component of this overlap and age-associated hypervariable CpGs also correlated significantly with CIN2+ status, further strengthening our previous findings [7]. We stress that even those PCGT CpGs that were identified as undergoing age-associated hypermethylation in other tissues (for example, whole blood) [7] were also more hypervariable in prospective CIN2+ samples and could indicate the risk of neoplastic transformation. This strong overlap between hypermethylated aCpGs and hypervariable DVCs is consistent with a model in which differential exposure to risk factors accumulates with age, thus generating the observed stochastic epigenetic variability. That these methylation changes and overlaps are not due to changes in cell-type composition is supported by many studies [7,46-48]. We also observed here that changes in cell-type composition were more likely to be captured by age-independent variable CpGs (vCpGs), defined as CpGs that showed the largest (age-adjusted) variation across all normal samples. Specifically, these maximally varying vCpGs exhibited fairly large (> 80%) changes in methylation, did not overlap with DVCs, and accordingly were neither enriched for PCGTs nor discriminatory of prospective CIN2+ status (Additional file 9). In fact, vCpGs were enriched for Gene Ontology terms related to extracellular space and mesenchymal features, including also many cell differentiation markers (Additional file 16), and thus it is possible that methylation variation in these CpGs reflects variations in the epithelial to mesenchymal and stromal cell ratio. Since risk CpGs were not enriched for these stromal and mesenchymal features, it supports the view that their observed methylation changes reflect clonal heterogeneity within the epithelial cell population only.

The reliability of the methylation data generated from the ARTISTIC cohort is strongly supported by emerging biology and successful validations in two independent data sets. Nevertheless, to further check the reliability of the Infinium methylation data, we compared the β-values to those obtained using Methylight. Matched Infinium-Methylight data were available for SOX1 and WT1 in 48 LBC samples (set 1) [49]. We found statistically significant agreement between the two data types for both SOX1 and WT1 (Additional file 17).

Unfortunately, the limited coverage of the Infinium 27 K array (only 0.1% of the CpGs present in the human genome [50]) means that we could not fully explore the spatial methylation patterns around the identified risk CpG sites. As shown in Hansen et al. [3] in the context of cancer, differential variability is associated with increased spatial variability and loss of stability of the sharp methylation boundaries. Thus, it will be interesting to explore the spatial variability around the identified CpG risk sites with a more comprehensive and unbiased technology such as the Infinium 450 K methylation beadarray [51], as this may reveal a similar loss of methylation boundaries surrounding these sites.

Conclusions

We have demonstrated that variability in DNAm, which is associated with age and other factors, and which occurs well in advance (at least 3 years) of the first morphological neoplastic changes, is associated with the risk of neoplastic transformation. More generally, we have demonstrated that inter-individual epigenetic variance is an intrinsic characteristic of cells that become neoplastic.
Additional file 4: Methylation profiles of 10 of the top hypermethylated DVCs in the ARTISTIC cohort (all 10 shown are also among the 140 risk CpGs). Green denotes normal samples and blue denotes prospective CIN2+ cases.

Additional file 5: PCGT enrichment odds ratio (OR) among the top 500 DVCs and the corresponding relative odds ratio (ROR) of PCGT enrichment (ROR = OR(more variable in future CIN2+)/OR(less variable in future CIN2+)). Also shown is the expected ROR for the null case where the top 500 CpGs were selected after a random permutation of sample labels. The P-value reflects the significance of the difference between the observed and null ROR.

Additional file 6: Gene Set Enrichment Analysis using a one-tailed Fisher’s exact test of the top 500 differentially variable CpGs (DVCs), done separately for those with increased variance in future CIN2+ cases, and those with decreased variance in future CIN2+ cases. The green line indicates FDR = 0.05. False discovery rate (FDR; x-axis). Red points indicate the top 500 vCpGs.

Additional file 7: The 644 age-associated CpGs (FDR < 0.05). We provide the Illumina probe ID, Entrez ID, gene symbol, t-statistic and P-value from linear regression against age, and estimated q-value (FDR).

Additional file 8: Heatmap of P-values of association between the singular vectors of a singular value decomposition on the inter-array normalized adjusted data, with experimental ( Bisulfite conversion efficiency controls (BSCE) 1 and 2, beadchip) and phenotypic factors (CIN2+ status, HPV status and age). P-values were estimated using t-tests (CIN2+ and HPV status), linear regression (age and BSCE BSCE: bisulfite conversion efficiency) and ANOVA (beadchip). Color codes: P < 1e-10 (red dark), P < 1e-5 (red), P < 0.001 (orange), P < 0.05 (pink), P > 0.05 (white).

Additional file 9: Age-associated CpGs and variable CpGs and their relation to CIN2+ status. (a) Scatterplot of t-statistics of the 644 age-associated CpGs (FDR < 0.05). The t-statistics relative to CIN2+ status (y-axis) are plotted against their age associated t-statistics (x-axis). Colored CpGs denote the 175 age-PCGT CpGs (skyblue = age-hypermethylated; orange = age-hypomethylated). The number of CpGs in each quadrant is given and the associated P-value is from a Fisher-exact test. (b) Example methylation profile (beta) of a CpG (cg00003235) undergoing age-associated hypomethylation and of one (cg07408456) undergoing hypomethylation. Red lines denote linear regression fits with associated P-values. (c) PCGT enrichment odds ratios (OR) for the top 500 age-hypermethylated (up) CpGs, the top 500 age-hypomethylated (dn) CpGs and the top 500 vCpGs. The green line denotes the null OR = 1, and 95% confidence intervals are shown. (d) Example methylation profile of an age-independent variable CpG (vCpG). (e) Scatterplot of all 24,039 CpG t-statistics (CIN2+ status, y-axis) against the corresponding estimated false discovery rate (FDR, x-axis). Red points indicate the top 500 vCpGs. The green line indicates FDR = 0.05.

Additional file 10: Comparison of mean methylation levels of the age-hypermethylated CpGs identified in ARTISTIC in set 1. Set 1 consists of 30 normal LBC samples and 16 LBC samples exhibiting dysplasia (CIN2+). The P-value is from a Wilcoxon rank sum test.

Additional file 11: The 140 risk CpGs as identified using EVORA in the ARTISTIC cohort. We provide the Illumina probe ID, Entrez ID, gene symbol, the ratio of age-adjusted variance in future CIN2+ cases relative to controls, the statistic of age-associated differential methylation change, and finally the t-statistic of differential methylation change between prospective CIN2+ and controls.

Additional file 12: Independent gene expression analysis of risk genes. (a) Average relative mRNA expression levels of 86 risk genes that could be mapped to the expression arrays of the integrated mRNA data set, comparing levels across 42 normal cervical samples (green) and 74 cervical cancers (red). The P-value is from a one-sided Wilcoxon rank sum test. (b) Corresponding t-statistics of differential expression (y-axis) of the 86 genes against -log10(P-value). The number of genes passing P > 0.05 threshold and that are over-/underexpressed in cancer are given. The P-value is from a binomial test (22 + 14 = 36 trials under the null that there is an equal chance of under- or overexpression). (c) Comparison of the observed binomial test P-value in (b) (vertical red line) to those binomial test P-values obtained from 1,000 Monte Carlo runs (green histogram), in which 86 genes were selected at random from the integrated expression set. The P-value shows the fraction of runs which more extreme P-values than the observed one. This Monte Carlo analysis therefore corrects for any bias in assuming that there is an equal null probability of under- or overexpression.

Additional file 13: DNA methylation and HPV status. (a) Expected number of false positives (NFP, y-axis) is plotted against the number of positives (NP, x-axis) for CpGs associated with HPV status using surrogate variable analysis (SVA) and all 152 samples in the ARTISTIC cohort. (b) Boxplot comparing the EVORA risk scores of the 152 samples against HPV status. The P-value is from a Wilcoxon rank sum test. (c) As (a), using SVA with HPV status as the phenotype but now only using the 77 samples that remained disease-free. (d) As (a), using SVA with HPV status as the phenotype but now only using the 75 samples that developed a CIN2+. In (a, c, d), the green dashed line indicates the null-line of no association. We note that even in (d) the association is very marginal since the FDR for the top 100 CpGs is over 50%.

Additional file 14: Correlation EVORA scores with CpG island methylation. (a) Left panel: average beta methylation level over all CpG mapping to CpG islands (excluding the 140 risk CpGs) on the y-axis versus the CIN2+ sample index. A partitioning around medoids algorithm ( pam from package cluster) was used to cluster the samples into two clusters of relative high and low methylation, and the samples have been ordered and colored accordingly. Right panel: boxplot of the EVORA risk scores defined over the 140 risk CpGs in the same set of CIN+ samples, grouped according to the clustering in (a). The P-value is from a Wilcoxon rank sum test. (b) Exactly as (a), but now for the cervical cancer samples of set 2.

Additional file 15: Consensus clustering heatmap of the 152 ARTISTIC samples over the top 1,000 most variable CpGs (vCpGs). Color codes in the heatmap: yellow, beta < 0.3; skyblue, 0.3 < beta < 0.5; blue, beta > 0.7. The bars above the heatmap indicate the consensus clusters (three clusters were optimal), HPV status (black = control, red = risk). As (a), e, grey = HPV-negative, prospective CIN2+ status (black = prospective CIN2+, grey = control) and EVORA risk score (green = risk score < 0.1, red = risk score > 0.1).

Additional file 16: Gene Set Enrichment Analysis using a one-tailed Fisher’s exact test of the top 500 variable CpGs (vCpGs) against the Molecular Signatures Database (MSigDB, Broad Institute) [25]. The columns label the gene list, the number of genes in the list, the number of genes passing the SVA with HPV status as the phenotype but now only using the 75 samples that developed a CIN2+. In (a, c, d), the green dashed line indicates the null-line of no association. We note that even in (d) the association is very marginal since the FDR for the top 100 CpGs is over 50%.

Additional file 17: Comparison of Methylight (PMR-value) based quantification of methylation (y-axis) with Infinium 27 K β-value (x-axis) for two of the identified risk genes (SOX7 and WT1) across the 48 LBC samples (set 1). The β-value on the 27 K array closest to the transcription start site and to the Methylight Cpgs was used. The P-value is from a correlation test, testing the significance of the Spearman rank correlation. Red denotes the 18 CIN2+ samples, green denotes the 30 CIN2- samples.

Abbreviations
cpG: age-associated CpG; ARTISTIC: A Randomised Trial of HPV Testing in Primary Cervical Screening; AUC: area under the curve; bp: base pair; CIMP: CpG island methylator phenotype; CIN2+: cervical intraepithelial neoplasia of grade 2 or higher; COPA: Cancer Outlier Profile Analysis; DMC: differentially methylated CpG; DNAm: DNA methylation; DVC: differentially variable CpGs; EVORA: Epigenetic Variable Outliers for Risk Prediction Analysis; FDR: false discovery rate; HPV: human papilloma virus; LBC: liquid-based cytology; PCGT: polycomb group target; vCpG: variable CpG.
Acknowledgements
This work was funded by the Eve Appeal, a grant from the UCLH/UCL Comprehensive Biomedical Research Centre, the NIHR Health Technology Assessment Programme, the Department of Health NIHR Biomedical Research Centres (BRC) funding scheme. AET was supported by a Heller Research Fellowship. HCK receives support from the Manchester NIHR BRC.

We wish to thank the University of Manchester for financial support. We are particularly grateful to the women who have participated in the ARTISTIC trial and to the entire medical, nursing, and administrative staff who work on the ARTISTIC trial.

Author details
1Statistical Genomics Group, Paul O’Gorman Building, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK. 2Department of Women’s Cancer, UCL Elizabeth Garrett Anderson Institute for Women’s Health, University College London, 74 Huntley Street, London WC1E 6AU, UK. 3Department of Gynecology and Obstetrics, Innbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. 4School of Cancer and Imaging Science, Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Oxford Road, Manchester M13 9WL, UK.

Authors’ contributions
AET designed and performed the statistical analyses. MW designed the study. HCK and AS contributed samples. AJ helped with processing of the samples. JZ helped with statistical analyses. U helped with funding. AET and MW wrote the manuscript. All authors have read and approved the manuscript for publication.

Competing interests
The authors declare that they have no competing interests.

Received: 17 January 2012 Revised: 13 March 2012 Accepted: 27 March 2012 Published: 27 March 2012

References
1. Feinberg AP, Izzary RA: Evolution in health and medicine Sackler colloquium: Stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc Natl Acad Sci USA 2010, 107(Suppl 1):1757-1764.
2. Feinberg AP, Izzary RA, Fradin D, Aryee MJ, Murakami P, Aspelund T, Eirkosdottir G, Harris TB, Launer L, Gudnaison V, Fallon MD: Personalized epigenomic signatures are that stable over time and covary with body mass index. Sci Transl Med 2010, 2:49ra67.
3. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, Feinberg AP: Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011, 43:768-775.
4. Bibikova M, Fan J: Genome-wide DNA methylation profiling. Wiley Interdiscip Rev Syst Biol Med 2010, 2:210-223.
5. Kittchener HC, Almonte M, Gilmah C, Dowie R, Strykovy B, Sargent A, Roberts C, Desai M, Peto J: AET: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009, 13:1-150, iii-v.
6. Kittchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Strykovy B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J: HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10:672-682.
7. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramsay SJ, Weisenberger DJ, Shen H, Campan M, Nourouzi H, Bol C, Maxwell AP, Savage DA, Mueller-Holzer E, Marsch C, Kogan G, Gashey SA, Jones A, Beck S, Wagner W, Laird PW, Jacobsen I, Widschwendter M: Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 2010, 20:440-446.
8. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210.
9. Scorto L, Narayan G, Ndula SV, Arias-Pulido H, Subramaniam S, Schneider A, Kaufmann AM, Wright JD, Pothers B, Mansukhani M, Murtv Y: Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 2008, 47:755-765.
10. Zhao Y, Kuck R, Nan B, Ota I, Weiss SJ, Trimble CL, Feorin ER, Choi KR: Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res 2007, 67:10163-10172.
11. Pyleon D, Newton MA, Lambert PF, de Boon JA, Sengupta S, Marst CJ, Woodword CD, Connor JP, Haugen TH, Smith EM, Kelsye KT, Turek LP, Ahlquist P: Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007, 67:4605-4619.
12. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007, 8R157.
13. Teschendorff AE, Gomez S, Arenas A, El-Ashry D, Schmidt M, Gehrmann M, Caldas C: Improved prognostic classification of breast cancer defined by antigenic activation patterns of immune response pathway modules. BMC Cancer 2010, 10:604.
14. Teschendorff AE, Nadeni A, Barbosa-Morais NL, Caldas C: PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics 2008, 22:269-275.
15. Leek JT, Storey JD: A general framework for multiple testing depending. Proc Natl Acad Sci USA 2008, 105:18718-18723.
16. Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003, 100:9440-9445.
17. Du P, Zhang X, Huang CC, Jain N, Ribbe WA, Hou L, Lin SM: Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010, 11:586.
18. Laird PW: Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 2010, 11:191-203.
19. Snedecor GW, Cochran WG: Statistical Methods Iowa State University Press; 1989.
20. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Monte JC, Shah RB, Paik S, Rubio MA, Chinnainayalan A: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
21. Tian L, Tibshirani R: Adaptive index models for marker-based risk stratification. Biostatistics 2011, 12:68-86.
22. R: A language and environment for statistical computing. R Foundation for Statistical Computing. [http://www.r-project.org].
23. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006, 7:213-33.
24. Lee TL, Jenning RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isokoto H, Hulckami T, Abe K, Murray HL, Zucker JP, Yuan B, Bell GW, Holershemile E, Hannett NM, Sun K, Odom DT, Otte AP, Volkert TL, Bariel DP, Melton DA, Gifford DK, Jaenisch R, Young RA: Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006, 125:301-313.
25. Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550.
26. Balboomers JM, Jacobs MV, Marins MA, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 181:12-19.
27. Kittchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, Desai M, Mather J, Turner A, Moss S, Peto J: A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer 2011, 47:864-871.
28. Sator MA, Dovinon DC, Jones TR, Catoan JCA, Prince ME, Carey TE, Rozek LS: Genome-wide methylation and expression differences in HPV (+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 2011, 6:771-787.
29. Stelos BS, Yi Y, Ely K, Carter J, Eyal E, Zhang X, Shyr Y, Murphy BM, Cmelak AJ, Burke BB, Netterville JL, Levy S, Yabrosh W, Chung CH: Gene expression differences associated with human papillomavirus
status in head and neck squamous cell carcinoma. Clio Cancer Res 2006, 12:701-709.

30. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TL, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simmons L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Hale R, Laird PW. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38:787-793.

31. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pellkoski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Nexviai P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K. Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.

32. Fang P, Tuncan S, Rinner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Vale A, Massague J, Nolon L, Vahdat LT, Moynahan ME, Chan TA. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 2011, 3, 75ra25.

33. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010, 7:299-313.

34. Bracken AP, Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009, 9:773-784.

35. Johnstone SE, Baylin SB. Stress and the epigenetic landscape: a link to the pathobiology of human diseases?. Nat Rev Genet 2010, 11:806-812.

36. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009, 10:269-304.

37. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011, 17:330-339.

38. Wilsman GB, Njihuis ER, Hoque MO, Reesink-Peters N, Koning AJ, Volders HH, Buikema HJ, Boezen HW, Hollema H, Schuureng E, Sidsky D, van der Zee AG. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer 2006, 119:1908-1914.

39. Herman L, Hubert P, Herf M, Kusterma M, Hennetin Y, Boussagrin L, Boniver J, Delvenne P. The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context. Eur J Immunol 2010, 40:3075-3084.

40. Kersemakers AM, van de Vijver MJ, Xenter GG, Fleuren GJ. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer 1999, 26:346-354.

41. Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, Muller-Kersemaekers AM, van de Vijver MJ, Kenter GG, Fleuren GJ. Cancer Genomics: Identification of a CpG island methylator phenotype that defines a distinct subgroup of cervical cancer. Cancer Cell 2010, 17:510-522.

42. Lin YW, Chung MT, Lai HC, De Yan M, Shih YL, Chang CC, Yu MH. Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clio Oncol 2009, 13:1665-1674.

43. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, Chang CC, Yu MH. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer 2008, 123:161-167.

44. Missiaou N, Hmisa S, Traebel A, Traere C, Mokri M, Dante R, Frappart L. Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. Pathol Res Pract 2011, 207:37-42.

45. Lin CJ, Lai HC, Wang KH, Hsung CA, Liu HW, Ding DC, Hsieh CY, Chu TY. Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results. Am J Obstet Gynecol 2011, 204:21.e21-27.

46. Miangawa S, Hinkal G, Kim HS, Shen L, Zhang L, Zhang J, Zhang N, Liang S, Donehower LA, Issa JP. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 2010, 20:332-340.

47. Ralyan VR, Down TA, Maslau S, Andrew T, Yang TP, Beyan H, Whitaker P, McCarrn GT, Finer S, Valdes AM, Leslie RD, Deloukas P, Spector TD. Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. Genome Res 2010, 20:434-439.

48. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Guyther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ, Widschwendter M. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One 2009, 4:e8274.

49. Apostolidou S, Hadwim R, Bumell M, Jones A, Baff D, Pyndiah N, Mould T, Jacobs IJ, Beddows S, Kocjan G, Widschwendter M. DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer 2009, 125:2995-3002.

50. Beck S. Taking the measure of the methylome. Nat Biotechnol 2010, 28:1026-1028.

51. Sandoval J, Heyn HA, Morian S, Serra-Musach J, Pujana MA, Bibikova M, Esteller M. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 2011, 6:692-702.